2013. Akt–the Mammalian Target of Rapamycin (mTOR) Pathway Inhibition Increases Cervical Cancer Cell Chemosensitivity to Active Form of Irinotecan (SN-38). International Journal of Integrated Health Sciences. 1, 1 (Sep. 2013), 13–21.